{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:01Z","timestamp":1778681701555,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12185-025-04148-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:49:35Z","timestamp":1767430175000},"page":"737-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL"],"prefix":"10.1007","volume":"123","author":[{"given":"Kohei","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Nakagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakuei","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Shimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohta","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikane","family":"Kikushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"12","key":"4148_CR1","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871\u20139. https:\/\/doi.org\/10.1182\/blood-2003-06-1841.","journal-title":"Blood"},{"issue":"15","key":"4148_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1214561.","journal-title":"N Engl J Med"},{"issue":"4","key":"4148_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534\u201344. https:\/\/doi.org\/10.1111\/bjh.15051.","journal-title":"Br J Haematol"},{"issue":"10","key":"4148_CR4","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1002\/cam4.2347","volume":"8","author":"EHL Chan","year":"2019","unstructured":"Chan EHL, Koh LP, Lee J, De Mel S, Jeyasekharan A, Liu X, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019;8(10):4626\u201332. https:\/\/doi.org\/10.1002\/cam4.2347.","journal-title":"Cancer Med"},{"issue":"10","key":"4148_CR5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","volume":"24","author":"S Vardhana","year":"2018","unstructured":"Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018;24(10):2133\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.009.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"4148_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"10254","key":"4148_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"1","key":"4148_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"18","key":"4148_CR9","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1182\/bloodadvances.2021004880","volume":"5","author":"JL Crombie","year":"2021","unstructured":"Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, et al. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021;5(18):3563\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2021004880.","journal-title":"Blood Adv"},{"issue":"5","key":"4148_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","volume":"38","author":"A Chiappella","year":"2024","unstructured":"Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024;38(5):1107\u201314. https:\/\/doi.org\/10.1038\/s41375-024-02213-x.","journal-title":"Leukemia"},{"issue":"13","key":"4148_CR11","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DD Twa","year":"2014","unstructured":"Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062\u20135. https:\/\/doi.org\/10.1182\/blood-2013-10-535443.","journal-title":"Blood"},{"issue":"11","key":"4148_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.012","volume":"21","author":"Z Ahmed","year":"2021","unstructured":"Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, et al. Primary mediastinal B-cell lymphoma: a 2021 update on genetics, diagnosis, and novel therapeutics. Clin Lymphoma Myeloma Leuk. 2021;21(11):e865. https:\/\/doi.org\/10.1016\/j.clml.2021.06.012.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"4148_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"1","key":"4148_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68\u201383. https:\/\/doi.org\/10.1182\/blood-2017-07-740993.","journal-title":"Blood"},{"issue":"34","key":"4148_CR15","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","volume":"37","author":"P Armand","year":"2019","unstructured":"Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291\u20139. https:\/\/doi.org\/10.1200\/JCO.19.01389.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4148_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.2022019340","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141\u20135. https:\/\/doi.org\/10.1182\/blood.2022019340.","journal-title":"Blood"},{"issue":"12","key":"4148_CR17","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s10147-024-02627-8","volume":"29","author":"K Kato","year":"2024","unstructured":"Kato K, Nakamura S, Wakana A, Koh Y, Izutsu K. Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study. Int J Clin Oncol. 2024;29(12):1977\u201383. https:\/\/doi.org\/10.1007\/s10147-024-02627-8.","journal-title":"Int J Clin Oncol"},{"key":"4148_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108382","volume":"214","author":"W Song","year":"2020","unstructured":"Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol. 2020;214:108382. https:\/\/doi.org\/10.1016\/j.clim.2020.108382.","journal-title":"Clin Immunol"},{"key":"4148_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914780","author":"MA P\u00e9rez-Moreno","year":"2023","unstructured":"P\u00e9rez-Moreno MA, Ciudad-Guti\u00e9rrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Mart\u00edn L, Flores-Moreno S. Combined or sequential treatment with immune checkpoint inhibitors and Car-T cell therapies for the management of haematological malignancies: a systematic review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241914780.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4148_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356. https:\/\/doi.org\/10.1038\/nbt.4195.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4148_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, et al. Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024;8(2):453\u201367. https:\/\/doi.org\/10.1182\/bloodadvances.2023011287.","journal-title":"Blood Adv"},{"issue":"2","key":"4148_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"1","key":"4148_CR23","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","volume":"132","author":"EA Chong","year":"2018","unstructured":"Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Blood. 2018;132(1):4198. https:\/\/doi.org\/10.1182\/blood-2018-99-119502.","journal-title":"Blood"},{"issue":"1","key":"4148_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-023-11536-4","volume":"23","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Mu W, Wang C, Zhuo Z, Xin Y, Li H. Ray of dawn: anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in lymphoma patients. BMC Cancer. 2023;23(1):1019. https:\/\/doi.org\/10.1186\/s12885-023-11536-4.","journal-title":"BMC Cancer"},{"issue":"2","key":"4148_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70091","volume":"9","author":"J Galtier","year":"2025","unstructured":"Galtier J, Mesguich C, Sesques P, Dupont V, Bachy E, Di Blasi R, et al. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry. Hemasphere. 2025;9(2):e70091. https:\/\/doi.org\/10.1002\/hem3.70091.","journal-title":"Hemasphere"},{"issue":"16","key":"4148_CR26","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","volume":"7","author":"A Major","year":"2023","unstructured":"Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023;7(16):4528\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2023010016.","journal-title":"Blood Adv"},{"issue":"7","key":"4148_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026\u201338. https:\/\/doi.org\/10.1182\/blood.2021012634.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04148-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04148-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04148-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:29:52Z","timestamp":1778678992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04148-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4148"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04148-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}